PKN1 and prostate cancer: Hence, PRK1 is now recognized as a key target in androgen-responsive prostate cancer, including in castrate-resistant prostate cancer (CRPC), the metastatic and lethal form of the disease that occurs following androgen deprivation therapy [47–49].